Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial

Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial

Abstract Aims Diabetes mellitus (DM) is common in heart failure with preserved ejection fraction (HFpEF). Patients with DM and heart failure with reduced ejection fraction have higher levels of cardiac, profibrotic, and proinflammatory biomarkers relative to non‐diabetics. Limited data are available...

Full description

Bibliographic Details
Main Authors: Corrado De Marco, Brian L. Claggett, Simon deDenus, Michael R. Zile, Thao Huynh, Akshay S. Desai, Martin G. Sirois, Scott D. Solomon, Bertram Pitt, Jean L. Rouleau, Marc A. Pfeffer, Eileen O'Meara
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:ESC Heart Failure
Subjects:
Heart failure
Preserved left ventricular function
Diabetes
Biomarker
Spironolactone
Online Access:https://doi.org/10.1002/ehf2.13153

Internet

https://doi.org/10.1002/ehf2.13153

Similar Items